Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Sells $399,523.80 in Stock

Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Junlin Ho sold 9,039 shares of Scholar Rock stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $44.20, for a total value of $399,523.80. Following the completion of the transaction, the general counsel now directly owns 195,037 shares of the company’s stock, valued at approximately $8,620,635.40. This represents a 4.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Scholar Rock Stock Up 4.1 %

Shares of NASDAQ:SRRK traded up $1.75 on Tuesday, hitting $44.88. 1,004,933 shares of the company’s stock were exchanged, compared to its average volume of 1,009,194. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. Scholar Rock Holding Co. has a 1-year low of $6.76 and a 1-year high of $46.19. The company has a market capitalization of $4.20 billion, a PE ratio of -19.10 and a beta of 0.52. The firm’s 50-day moving average is $39.58 and its 200 day moving average is $23.33.

Hedge Funds Weigh In On Scholar Rock

Several hedge funds have recently added to or reduced their stakes in SRRK. GAMMA Investing LLC lifted its position in shares of Scholar Rock by 51.8% during the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock worth $34,000 after buying an additional 269 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Scholar Rock by 1.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company’s stock worth $310,000 after acquiring an additional 379 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Scholar Rock by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company’s stock valued at $25,000 after acquiring an additional 514 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in Scholar Rock by 1,321.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock valued at $48,000 after acquiring an additional 1,031 shares in the last quarter. Finally, Cinctive Capital Management LP grew its holdings in shares of Scholar Rock by 7.2% during the third quarter. Cinctive Capital Management LP now owns 42,902 shares of the company’s stock worth $344,000 after purchasing an additional 2,869 shares during the last quarter. 91.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on SRRK shares. Truist Financial upped their target price on shares of Scholar Rock from $36.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, November 25th. Wedbush reiterated an “outperform” rating and issued a $47.00 price objective on shares of Scholar Rock in a research note on Thursday, January 9th. JPMorgan Chase & Co. lifted their target price on Scholar Rock from $18.00 to $31.00 and gave the company an “overweight” rating in a report on Monday, October 14th. BMO Capital Markets upped their price target on Scholar Rock from $34.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, October 11th. Finally, HC Wainwright lifted their price objective on Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $40.43.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.